Background: There is currently disagreement on the way of expressing the reversibility of airflow obstruction, with some evaluations based on the initial FEV(1) while others use predicted FEV(1) (according to age, gender and height).
Objectives: To test the relevance of expressing bronchodilator response as a percentage of predicted FEV(1), we evaluated the influence of morphological data on the response to bronchodilators in a population with a large range of predicted values.
Methods: We measured the change in FEV(1) after inhalation of 200 microg of salbutamol in 30 asthmatic subjects (15 adults and 15 children) in whom predicted FEV(1) ranged between 1.13 and 4.10 liters and analyzed the respective influence of initial and predicted FEV(1 )on bronchodilator response.
Results: We have shown a significant relationship between the absolute variation in FEV(1), in liters, and predicted FEV(1) (p = 0.0019). There was also a significant relationship between the absolute variation in FEV(1) and initial FEV(1), in liters (p = 0.02). This relationship was no longer significant (p = 0.8) when the variation and initial FEV(1) were both expressed as percentages of predicted FEV(1). In addition, multiple regression analysis showed that predicted FEV(1) was the only independent variable correlating with the response to bronchodilators.
Conclusion: This study showed the influence of predicted FEV(1) on bronchodilator response. This result provides an additional argument for expressing bronchodilator response as a percentage of predicted FEV(1).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000068419 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI).
Pediatr Pulmonol
January 2025
Pulmonary and Sleep Medicine, DeVos Children's Hospital, Grand Rapids, Michigan, USA.
Objective: We prospectively monitored rates of change for growth, body mass and composition, muscle strength, and FEV1 in 6-11-year-olds initiating ETI therapy, comparing them to those of US reference children. We assessed factors potentially contributing to rate of change and report ranges of individual variation.
Methods: Body composition was assessed using bioelectrical impedance analysis (BIA), and rates of change were analyzed using linear mixed effects regression models.
Total immunoglobulin E levels in induced sputum reflect asthma control status.
Clin Transl Allergy
January 2025
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Background: Most patients with severe asthma are sensitized to at least one allergen. Whether local immunoglobulin E (IgE) in induced sputum reflects asthma control status has not been investigated.
Methods: Patients with asthma were classified as well controlled, partly controlled, and uncontrolled asthma (UCA) according to Global Initiative for Asthma 2022 guidelines.
Right ventricular strain impairment due to hypoxia in patients with COPD: a post hoc analysis of two randomised controlled trials.
Open Heart
January 2025
Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland
Background: Hypoxic pulmonary vasoconstriction leads to an increase in pulmonary artery pressure (PAP) and potentially right heart failure in healthy individuals and patients with respiratory diseases. Previous studies in patients with chronic obstructive pulmonary disease (COPD) exposed to hypobaric hypoxia have shown an increase in PAP, while traditional echocardiographic parameters revealed only minimal changes at high altitude. Speckle-tracking-derived analysis is potentially more sensitive to assess right ventricular (RV) function and we used this method to investigate the impact on RV function of patients with COPD ascending to high altitude and compared the results with the traditional echocardiographic parameters.
View Article and Find Full Text PDFVanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Lancet Respir Med
December 2024
Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 6-11 years.
View Article and Find Full Text PDFVanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Lancet Respir Med
December 2024
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. Electronic address:
Background: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor compared with standard of care elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!